October 25, 2016
IDT Biologika Wins Major Contract
IDT Biologika, a globally integrated manufacturer of vaccines and biopharmaceuticals, with over 1600 employees worldwide, announces today that the Biomedical Advanced Research and Development Authority (BARDA) within the office of the Assistant for Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS) has awarded the company an Indefinite Quantity, Indefinite Delivery (IDIQ) contract1 to provide live virus filling and finishing services with an initial commitment of US $100,000, subject to task order(s) for a maximum amount of US $50 million. BARDA seeks to establish fill/finish capabilities for use of live-vectored virus products in clinical development through licensure. BARDA has contracted with IDT Biologika to provide services to support cGMP and non-GMP filling and finishing of a variety of medical countermeasure products. The company will initially provide services to support live virus/vectored vaccine fill finish and potentially for small molecule injectables, large molecule sterile injectables, monoclonal antibodies and other development-stage and FDA-approved medical countermeasures.
“The BARDA award showcases IDT Biologika’s global capabilities and highlights the benefits of IDT’s recent expansion in the United States and Canada,” said José Ochoa, Chief Business Officer of IDT Biologika Corporation and BARDA’s primary point of contact at the company. “We look forward to continuing to develop a strong relationship with BARDA and other US government agencies.”